WCM Investment Management LLC Boosts Position in Insmed, Inc. $INSM

WCM Investment Management LLC increased its holdings in Insmed, Inc. (NASDAQ:INSM) by 51.5% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,707 shares of the biopharmaceutical company’s stock after buying an additional 5,339 shares during the period. WCM Investment Management LLC’s holdings in Insmed were worth $2,408,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in INSM. Norges Bank acquired a new position in Insmed during the fourth quarter worth about $506,625,000. RTW Investments LP lifted its holdings in shares of Insmed by 57.0% in the fourth quarter. RTW Investments LP now owns 4,842,879 shares of the biopharmaceutical company’s stock valued at $842,855,000 after purchasing an additional 1,758,321 shares in the last quarter. Orbis Allan Gray Ltd acquired a new stake in shares of Insmed in the second quarter valued at approximately $153,389,000. State Street Corp grew its position in shares of Insmed by 30.6% in the fourth quarter. State Street Corp now owns 5,201,744 shares of the biopharmaceutical company’s stock valued at $905,312,000 after purchasing an additional 1,217,390 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of Insmed by 5.7% during the 4th quarter. Vanguard Group Inc. now owns 21,076,344 shares of the biopharmaceutical company’s stock worth $3,668,127,000 after purchasing an additional 1,140,524 shares in the last quarter.

Analysts Set New Price Targets

Several research analysts recently issued reports on INSM shares. HC Wainwright restated a “buy” rating and set a $220.00 price objective on shares of Insmed in a research report on Monday. Bank of America upped their price objective on Insmed from $211.00 to $213.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. Barclays increased their price objective on Insmed from $231.00 to $237.00 and gave the company an “overweight” rating in a research note on Wednesday, April 1st. Morgan Stanley upgraded Insmed from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $166.00 to $212.00 in a research report on Monday, March 30th. Finally, Wells Fargo & Company lifted their price objective on Insmed from $160.00 to $161.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Insmed has an average rating of “Moderate Buy” and an average target price of $209.13.

Insiders Place Their Bets

In other Insmed news, CFO Sara Bonstein sold 2,404 shares of the firm’s stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total value of $245,857.08. Following the sale, the chief financial officer directly owned 69,082 shares of the company’s stock, valued at approximately $7,065,016.14. This trade represents a 3.36% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Roger Adsett sold 2,370 shares of Insmed stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $102.27, for a total value of $242,379.90. Following the completion of the sale, the chief operating officer owned 98,603 shares of the company’s stock, valued at $10,084,128.81. This trade represents a 2.35% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders have sold 54,590 shares of company stock valued at $5,793,738. 2.10% of the stock is owned by company insiders.

Insmed Stock Down 1.2%

Shares of NASDAQ INSM opened at $107.02 on Tuesday. Insmed, Inc. has a 1 year low of $90.39 and a 1 year high of $212.75. The firm’s 50 day moving average price is $105.79 and its 200 day moving average price is $135.16. The firm has a market cap of $23.20 billion, a P/E ratio of -18.61 and a beta of 0.78. The company has a debt-to-equity ratio of 0.80, a quick ratio of 4.10 and a current ratio of 4.47.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.14. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. The firm had revenue of $305.96 million during the quarter, compared to analysts’ expectations of $300.81 million. During the same period in the previous year, the company earned ($1.42) EPS. Insmed’s revenue for the quarter was up 229.7% on a year-over-year basis. As a group, sell-side analysts anticipate that Insmed, Inc. will post -2.43 earnings per share for the current year.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.